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Abstract
Inflammatory bowel disease risk factors include poor diet, and corresponding low
intake of dietary fiber, specifically prebiotics, which is fermented by the gut microbiota. Dietary fibers, many of which are potential prebiotics, have hundreds to thousands of unique chemical structures that may promote bacteria or bacterial groups
to provide beneficial health effects. In vitro and in vivo animal models provide some
support for the use of prebiotics for inflammatory bowel disease through inflammation reduction. Studies using prebiotics in patients with inflammatory bowel disease are limited and focus on only a select few prebiotic substances.
Keywords: Inflammatory bowel disease, Ulcerative colitis, Crohn disease, Prebiotics, Fiber

Introduction
Prebiotics are fermentable carbohydrates that vary greatly in chemical structure, giving rise to digestion by specific gut microbiota and eliciting discrete
beneficial functions. Although hundreds to thousands of fermentable dietary
fibers, which are potential prebiotic substances, exist in nature, use of prebiotics in research is often limited to a few distinct structural types. Research
centered on prebiotic interventions to beneficially modify the gut milieu is
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increasing and includes modifying microbiota, improving intestinal barrier
function, and producing beneficial metabolites for both local and systemic
health benefit. Despite increasing use, limited data exist for prebiotic benefit for certain conditions, including inflammatory bowel disease (IBD). This
article reviews prebiotic types and the various ways in which they modify
the gastrointestinal tract related to IBD. The use of select prebiotics in IBD
is described in detail, highlighting their potential effectiveness, as well as
the lack of evidence, for their clinical use. Recommendations for future research are made.
Prebiotics: Definition and Structure
The term prebiotics has, over time, undergone some changes in its definition, although it still adheres to the concept of carbohydrates that make
their way to the large intestine where they are fermented and promote beneficial bacteria.1 At the time of the original definition in the 1990s, a focus
was put on oligosaccharides, and larger soluble fibers, because it was found
that certain of such carbohydrates promoted 2 genera of beneficial bacteria, namely Bifidobacterium and Lactobacillus.2 The term prebiotics became
synonymous with oligosaccharides, such as fructooligosaccharides (FOS)
and galactooligosaccharides (GOS), as they were accepted in the scientific,
although not necessarily the regulatory, community to promote a healthy
colon through the favoring of these bacteria. It was true, too, that other dietary carbohydrates promote 1 or both of Bifidobacterium spp and Lactobacillus spp, and in the scientific literature examples can be found that also
are claimed as prebiotic, such as resistant starch and b-glucans. However, as
more was learned regarding other relevant beneficial colonic bacteria and
the importance of maintaining a favorable gut ecosystem for health, it has
become apparent that the concept of prebiotics has a broader, and perhaps
more complicated, role in gut health.
Prebiotics are found within the larger class of carbohydrates known as
dietary fiber. These carbohydrates include all plant carbohydrates taken in
the diet, plus lignin, and although fibers can be broken down into various
subfractions, in the current discussion fiber may best be divided into fermentable and nonfermentable fibers. Because prebiotics are all fermentable, a case could be made for a beneficial effect of all fermentable fibers
and that they promote beneficial bacteria. Hence, the concept of prebiotics
could potentially take in many types of fermentable fibers comprising both
oligosaccharides and polysaccharides. In contrast, nonfermentable fibers are
recognized for their water-holding property and laxation capacity, although
it is not known whether nonfermentable fibers could also induce an environment in the colon in which beneficial bacteria might flourish.
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Fig. 1. Cell wall pectin chemical structure. AG, arabinogalactan; ARBN, arabinan; B,
borate; HG, homogalacturonan; PG, pectic galactan; RG I, rhamnogalacturonan I;
RG II, rhamnogalacturonan II. (Data from Hamaker BR, Tuncil YE. A perspective on
the complexity of dietary fiber structures and their potential effect on the gut microbiota. J Mol Biol 2014;426(23):3842; with permission.)

Perhaps what is not well recognized by scientists and clinicians specializing in gastrointestinal health and the gut microbiome is the broad and
complex range of dietary fiber chemical and physical structures that exist
(see the review by Hamaker and Tuncil,3 2014). All dietary fibers, and therefore prebiotics, are composed of 1 or more sugar units (e.g., glucose, fructose, galactose, arabinose) or sugar acids (e.g., galacturonic and glucuronic
acid) that are linked via glycosidic bonds. Although dietary fibers are chemically and physically classified in various ways, for the purpose of the current
discussion related to IBD, it is perhaps useful to think of them as (1) plant
cell wall polysaccharides of the cereals (mostly composed of cellulose, arabinoxylans, b-glucans, but also small amounts of pectin and even inulin in
wheat), legumes (cellulose, pectin, galactans), tubers (cellulose, pectin), and
fruits and vegetables (mostly composed of cellulose, pectins, xyloglucans);
(2) plant storage oligosaccharides and polysaccharides, such as starch (those
entering the large intestines being resistant starch) and inulin; (3) plant exudates (e.g., gum arabic); and (4) animal-based carbohydrates (e.g., galactooligosaccharides, chitin/chitosan). As discussed here, most prebiotics used
in human studies for patients with IBD are in the oligosaccharide and inulin
classes: classes 2 and 4, respectively. Plant polysaccharides can have complicated chemical structures (Fig. 1 for the example of pectin),3 which gut
bacteria can use through specialized abilities to access and metabolize certain structural components.
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Down to the strain level, colonic bacteria have encoded in their genomes
the ability to degrade certain carbohydrates they encounter and to absorb
and metabolize the simple sugars released. The authors have proposed that
there is high specificity of bacteria for carbohydrate chemical and physical
structures and that beneficial bacteria can potentially be favored through
fiber selection.3
Prebiotic Function
Prebiotic, or fermentable dietary fiber, function in the colon depends on several factors, including obvious ones like fiber type and structure, as well as
an individual’s gut microbiota community members and structure. Also relevant to prebiotic function are such things as cross-feeding, bacteriocins, and
phage communities that influence how fibers are used. However, it is likely
that prebiotic dietary fibers can shift the gut microbiome and have a beneficial effect on health, because the bacteria evolved under dietary stresses
and were selected for, in significant part, based on their ability to access
carbohydrates and use them efficiently for their maintenance and growth.
Fermentable dietary fibers function in the colon by providing essential
food to the microbiota. Because individual bacteria, and groups or consortia of bacteria, have different abilities to use carbohydrates and must compete with other bacteria for them, there is a growing recognition that mixtures of fibers are more likely to promote growth of a wider range of bacteria
than single fibers. Along with this, there is a generally accepted concept that
more diverse bacterial communities are better for health than less diverse
ones.4 Much still needs to be learned regarding fibers and their action in the
colon, and what mixtures are best suited for the microbiome and health, although some things are known. In addition to the function of FOS, GOS, and
inulin in promoting Bifidobacterium and Lactobacillus, certain other beneficial genera and groups of bacteria have been studied in relation to fiber
types for their promotion. The Clostridium clusters IV and IVa bacteria have
drawn interest because they are associated with the mucosal layer of the
gut epithelium, and contain several of the butyrogenic bacteria in the colon (i.e., Faecalibacterium prausnitzii, Eubacterium rectales, Roseburia infantalis); there is also some evidence that insoluble (and fermentable) fibers favor these groups.3,5,6
Inflammatory Bowel Disease
IBD is increasing, both in the United States and in less-developed countries.7,8 The disease is characterized by immune activation in the gastrointestinal tract, causing inflammation and damage to the mucosa or submucosa.

Rasmussen & Hamaker in Gastroenterol Clin N Am 46 (2017)

5

Ulcerative colitis (UC) differs from Crohn disease (CD) in presentation, with
disease activity focused on the colon and rectum in UC and intermittent disease activity throughout the gastrointestinal tract in CD. IBD is characterized
by both activated innate and adaptive immune responses, with response
varying by IBD type.9 Although a T-helper 1–type response is thought to be
predominant in CD and a T-helper 2–type response in UC, the stimulation
and deregulation of these pathways in each type of IBD is more complex
and not so clearly delineated.10
The cause of IBD is multifaceted, and a combination of genetic predisposition and environmental stimuli promote IBD. Genetic susceptibility to IBD is
greater in CD; genes involved in signaling between the immune system and
microbiota have been associated with IBD susceptibility (e.g., nucleotidebinding oligomerization domain– containing protein 2 [NOD2], interleukin
[IL]-23R, IL-10). An immune response in genetically predisposed individuals can be triggered by environmental stimuli through the modern lifestyle;
sometimes these are otherwise innocuous. For example, drugs (e.g., antibiotics, nonsteroidal anti-inflammatory drugs), as well as infectious agents,
stress, and diet, may all contribute to IBD.11 Also, environmental stimuli can
have opposing effects on IBD disease type; cigarette smoking increases CD
risk but may be protective in UC. Some of these environmental stimuli may
modify gut microbiota, creating an environment that is more susceptible to
IBD development.
What Is the Involvement of Microbiota in Inflammatory Bowel
Disease?
The gastrointestinal microbiota is composed of bacteria, viruses, and fungi,
but the manipulation of just the bacterial component of the microbiota is
the focus of the IBD literature to date. All components of the microbiota intimately interact with the host immune system, including communication
between bacterial species and dendritic cells (DCs) to drive differentiation
of T cells toward either an effector or regulatory T-cell response. In the context of IBD, it is not clear whether the microbiota drive changes in the host
immune system or the host changes the microbiota through aberrant immune activation; likely it is a combination of the two interactions that contributes to IBD susceptibility.
The involvement of the gut microbiota in IBD was recently reviewed.12,13
Evidence of the influence of the microbiota/immune system interaction on
IBD is convincing; however, alterations in specific microbiota that increase
IBD disease risk or disease course are not completely clear. Overall, patients with IBD have less microbial diversity and increased mucosal bacteria
than healthy individuals.12,14 Individual bacterial species also may differ between those with IBD and healthy individuals, with more adherent-invasive
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Escherichia coli and Enterobacteriaceae, among others,12 in those with IBD.
In addition, several taxa may be decreased, including Bifidobacterium and
F prausnitizii.12,15–17 CD recurrence has been associated with low levels of F
prausnitizii.18
Although differences in microbiota composition between healthy individuals and those with IBD provide insight into microbiota’s potential role in
IBD, this does not indicate how, or whether, these differences contribute an
altered intestinal milieu. Differing metabolites were found in fecal samples
between patients with CD and healthy concordant twins.19 Compared with
healthy subjects, fecal butyrate concentrations were lower in those with IBD
compared with healthy controls.20 Maintenance or improvement in butyrate
concentrations is especially important because butyrate is a primary energy
source for the colonic mucosa, contributes to gut epithelial barrier integrity,
and shows anti-inflammatory activity.21 More literature on the contribution
of microbial metabolites to IBD disease course is warranted.
Dietary Strategies to Minimize Progression and Symptoms of Inflammatory Bowel Disease: Is There a Niche for Prebiotics?
Management of IBD through medication (e.g., aminosalicylates, antibiotics, anti–tumor necrosis factor alpha therapy, and corticosteroids) is often
needed to control disease activity; however, medication management is not
always effective. This lack of efficacy may lead to uncontrolled inflammation
and complications such as rectal bleeding, bowel obstruction, and intestinal resection, the occurrence of which depends on IBD type. These complications, along with intermittent diarrhea, may lead to malnutrition and
weight loss. Whereas/although nutritional inadequacy, may be addressed
by elemental diets or parenteral nutrition; recommendations for IBD when
in remission or in less active disease suggest dietary fiber manipulation as
a component of treatment.
Low-fiber diets are recommended for acute exacerbation or strictures.
This minimization of fiber intake may be detrimental to encouraging a beneficial microbial environment. However, during remission, a high-fiber diet is
warranted to maintain normal bowel habit, minimize gastrointestinal symptoms, and promote a healthy intestinal milieu. These recommendations focus largely on the inclusion of dietary fiber in the context of a diet high in
fruits, vegetables, and whole grains. However, dietary fiber intake in the
United States is inadequate (17 g/d),22 as it is in other countries around the
world. Thus, supplementation with select fibers that target specific bacteria and other components of gut health is warranted. As highlighted earlier, a structure-function relationship exists with prebiotics, suggesting that
a specific prebiotic could be identified to target enhancement of a desired
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specific bacterial strain based on examining these structure-function relationships. However, on the whole, this has not been thoughtfully considered when selecting prebiotics, nor has it been fully researched. In addition,
because uncertainty surrounds the specific bacterial taxa and metabolites
that differ between both healthy individuals and those with IBD, as well as
between those with UC and CD, it is currently difficult to accurately identify
specific dietary modifiers for IBD because the targets of modification are not
clearly known. Despite this, investigators have attempted to provide prebiotic interventions in both animal models and in humans.
Use Of Prebiotics in in vitro and Animal Models as a Foundation for
the Use in Humans with Inflammatory Bowel Disease
A few studies have examined the effect of potential prebiotic fibers using
in vitro fermentation of microbiota from patients with IBD. Rose and colleagues23 (2010) showed the effect of a fabricated butyrate-producing fiber
on the microbiota communities of patients with IBD with inactive CD and
active UC. The test fiber was an alginate-based starch-entrapped microsphere, and application in vitro fermentation system resulted in slower fermentation than FOS, but with similar butyrate levels; a maintenance of low
pH better than FOS; and a reduction in patients with inactive CD of potentially harmful gut bacteria (species of Bacteroides, Enterococcus, Fusobacterium, and Veillonella) compared with FOS.
In recent studies in our laboratory at Purdue University on in vitro fecal fermentation assessment of dietary fibers on patients with CD and UC,
many patients had microbiota with low capacity to generate short-chain
fatty acids (SCFAs), which correlated with the loss of the Bacteroidetes phylum. Patients with CD and UC microbiota had lower diversity than healthy
controls. It seemed that the severity of dysbiosis dictates the SCFA production with fiber supplementation. When fed in vitro a mixture of fibers containing equal amounts of FOS, b-glucan, pectin, and arabinoxylan (soluble),
there was a promotion of SCFAs and gas production in the CD group that
was better than when any single fiber was given. In the fiber mixture group,
the Bacteroides genus was increased, although there was no significant pattern of microbiota change related to the fiber mixture among the individuals with CD and UC. Bacteroides was increased by all the fibers. Thus, in vitro human fecal fermentation analysis seems to have potential in screening
dietary fibers for prebiotic effect, but studies comparing in vitro with human
intervention results must still be done.
In animals, there are several studies using mostly the dextran sodium
sulfate model to induce UC in mice, which show a beneficial effect of prebiotics on gut bacteria. For instance, prebiotic fructans increased amounts
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of Bifidobacterium and Lactobacillus in colitis-induced mice.24,25 Larrosa and
colleagues26 (2009) studied the potential prebiotic effect of the noncarbohydrate phenolic compound, resveratrol, in rats with DSS-induced colitis
and found increased levels of Bifidobacterium and Lactobacillus, and lower
amounts of E coli and Enterobacteriaceae. In addition, in a mouse model of
colitis, FOS increased luminal Bifidobacterium and reduced disease activity.27
Overall, there is a good indication of prebiotic effect resulting in improvements in microbiota community structure in IBD-type conditions. A
more systematic approach toward understanding how prebiotics could optimally be used through the aforementioned, as well as additional, approaches
is desired (e.g., with maximum effect on creating favorable microbiota shifts,
with concomitant low levels of bloating and discomfort).
Use of Prebiotics in Humans with Inflammatory Bowel Disease: Are
They Effective?
In human studies reporting treatment outcomes in patients with IBD, degree
of disease activity is assessed through biomarkers (e.g., C-reactive protein,
fecal calprotectin, IL-10), established indices (Crohn disease activity index
[CDAI] or Harvey-Bradshaw index [HBI]), or self-report of specific outcomes
such as gastrointestinal symptoms or quality-of-life improvement. In addition, and germane to this topic, microbiota composition and metabolite
production (e.g., SCFAs) can be measured to identify the prebiotic capacity of the supplement, as well as to provide a potential mechanism for disease improvement.
As discussed here, prebiotics are often specific carbohydrate structures
that may be categorized as a type of dietary fiber. Although several researchers have shown that dietary fiber from whole foods and specific high-fiber
dietary patterns can influence IBD outcomes,28,29 no studies have been done
that examine the impact of specific prebiotic-containing whole foods on IBD.
Thus, evaluation of the literature to determine the impact of prebiotics on
IBD is limited to prebiotic supplementation (Table 1).
Mixed results exist for supplementation of fructan-based prebiotics. A
1-group, open-label study supplemented 15 g of FOS for 3 weeks in 10 patients with CD.30 Supplementation reduced the HBI score, increased fecal Bifidobacterium concentrations, and increased the percentage of IL-10–positive DCs. However, fluorescence in situ hybridization was used to assess
changes in microbiota, a method that may not be directly comparable with
more common sequencing methods used currently. In addition, the placebo
response could have contributed to benefits attributed to the FOS supplement.31 In a follow-up study by the same group, patients with CD were enrolled in a placebo-controlled randomized controlled trial (RCT) to test the
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Table 1. Human intervention studies administering prebiotics in individuals with inflammatory bowel disease
Study Design/
Intervention 			
Duration
Sample
Prebiotic

Clinical
Outcomes

Molecular/
Microbial Outcomes

Fructans
Lindsay et al,30
2006

One group,
Moderately active CD 15 g FOS
Decrease in HBI
open label
(HBI >5)
(70% oligofructose,
(9.8 [3.1] to 6.9
3 wk
n = 10
30% inulin)
[3.4], P = .01)
				
Decrease in CADI
				
(250.9 [77.8] to
				
220.6 [127.8], P = .39)
				
Increase in patient
				
and physician
				
global assessment
				
scores, P < .01
				
Increased borborygmi,
				
P = .049, and
				
flatulence severity,
				
P = .009
					
					
					
					
					
					
					
					
					
					
Benjamin et al,32
2011

Double-blind
Active CD
15 g FOS
RCT
(CDAI ≥ 220
(70% DP <10,
4 wk
plus increased
30% DP >10)
		
inflammation)
15 g maltodextrin
		
n = 103
control
				
				
				
				
				
				
				
				
				
				
				
				
				

Increase in fecal
Bifidobacterium,
P = .005; no
change in mucosal
Bifidobacterium,
P = .76
Increase in mucosal
Bifidobacterium in
those who entered
disease remission
(n = 4), P = .03
No change in CRP,
P = .12
Increase in
IL-10–positive
CD11c + DC
(30.1% [38%] to
53.3% [33%],
P = .06)
Increase in DC
TLR4 expression
(36.8% [32%] to
75.4% [7.9%],
P<.001)

No difference in
No difference in
clinically significant
Bifidobacterium
decrease in CDAI
(P = .20) or F. prausnitzii
(22% FOS and
(P = .95) between groups 		
39% placebo,
after treatment
P = .067)
No difference in CRP
No difference in those
(P = .32) or
achieving clinical
fecal calprotectin
remission (11% FOS
(P = .09) between
and 20% placebo,
groups after
P = .19)
treatment
More flatulence
Increase in
(P = .004),
IL-10–positive
borborygmi (P = .029), CD11c + DC
and abdominal pain
intensity ratio
(P = .048),
(1.3 [0.6] to
than placebo at
2.0 [1.6], P = .04)
treatment end
(continued on next page)
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Table 1 (continued). Human intervention studies administering prebiotics in individuals with inflammatory bowel disease
Study Design/
Intervention 			
Duration
Sample
Prebiotic

Clinical
Outcomes

De Preter et al,33
2013

Double-blind
Inactive or
10 g 1:1 OF-IN
Decrease in HBI
RCT
moderately active
10 g maltodextrin
from 4 to 3
4 wk
CD (HBI 0–12)
control
(P = .048) in
		
n = 67 		
prebiotic group, no
				
change in placebo;
				
decrease from 7 to
				
5 in moderately
				
active patients
				
with CD (P = .02)
				
32% dropout rate in
				
prebiotic group
				
vs 12% in placebo
				
because of side
				
effects,
				
P = .07
					
					
					
Casellas et al,34
2007

Double-blind
Mild to moderate
12 g oligofructoseRCT
UC (index of
enriched inulin
2 wk
Rachmilewitz 6–19) 12 g maltodextrin
		
n = 19 		
				
				
				
				
				

Molecular/
Microbial Outcomes
Increase in
Bifidobacterium
longum (P = .03)
and decrease in
Ruminococcus
gnavus (P = .03)
Disease activity
correlated with
B. longum
(r = 0.894, P = .02)
in patients with
active CD
Increase in relative
concentration of
acetaldehyde
(P = .001) and
butyrate (P = .001)
in OF-IN group

Decrease in clinical
Decrease in fecal
disease activity
calprotectin with
in both groups
oligofructose(P < .05), no difference enriched inulin
between groups
(P < .05)
Decrease in dyspepsia
No change in
scores with oligoinflammatory
fructose-enriched
mediator
inulin (P < .05)
release (P >.05)

Germinated Barley
Kanauchi et al,35
2003

One group,
Mild to moderate
20–30 g germinated
open label
UC
barley (48% protein,
24 wk
n = 21
35% fiber, 9% lipid)
				
				
				
				

Reduction in total
clinical activity
index score and
in 2 of the 6
components (blood
in stool, nocturnal
diarrhea)a

No difference
in biochemical
parametersb
Decrease in
erythema,
granularity,
and erosiona

FernandezOpen-label RCT UC in remission
20 g P. ovata seeds
Treatment effect
Banares et al,38
1y
n = 105
1.5 g mesalamine
not associated with
1999 			
20 g P. ovata seeds
probability of
			
plus mesalamine
relapse, P = .67
					

Increase in fecal
butyrate in
those taking
P. ovata seeds,
P = .018c

Fujimori et al,39
2009

No change in		
C-reactive protein,
P > .05

Plantago ovata

3-group,
UC in remission
randomized
n = 120
trial
		
4 wk		

2 x 109 CFU B. longum
4.0 g psyllium
2 x 109 CFU B. longum
plus 4.0 g psyllium

Improvement in
bowel function
subcomponent
of IBDQ, P = .04

Abbreviations: CRP, C-reactive protein; IBDQ, IBD quality-of-life questionnaire; OF-IN, oligofructose/inulin; RCT, randomized controlled trial; TLR,
Toll-like receptor.
a. P value not reported.
b. Biochemical parameters measured were not reported.
c. n = 7, specific treatment group not reported.
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effectiveness of 15 g of FOS on CD disease activity.32 No differences in clinical response existed between groups. In addition, no change in fecal Bifidobacterium or F. prausnitzii was seen with FOS intake, but the proportion of
IL-6–positive DCs decreased and the proportion of IL-10 DCs increased with
treatment. De Preter and colleagues33 conducted a double-blind, parallelgroup RCT using 10 g of fructan (1:1 inulin to oligofructose) versus a maltodextrin control. In the prebiotic group, butyrate was significantly increased
from baseline, and HBI decreased in the entire sample as well as in patients
with moderately active disease. In addition, Casellas and colleagues34 conducted a study with a mixture of inulin and oligofructose (BENEO Synergy
1) and reported decreases in fecal calprotectin in patients with mild to moderately active UC. Importantly, side effects were common in 3 of these studies, contributing to increased dropout in 2. Although most saw a beneficial
change in clinical disease activity indices, improvement in molecular outcomes were not consistent between studies.
Although fructan-containing compounds are the most well-known prebiotics, other fibers may have prebiotic capacity and thus may benefit patients with IBD. One such example is germinated barley. Composed of not
only fiber (cellulose, hemicellulose, and lignin), malted barley in the form
used in IBD studies (termed germinated barley foodstuff, GBF) contains protein and lipid as major and minor components, respectively, of the dietary
compound. Several studies by the same researchers reported a benefit of
this compound for patients with UC.35–37 In one study (see Table 1), these researchers provided patients with UC with 20 to 30 g of GBF for 24 weeks.35
Total clinical activity index score, as well as 2 subcomponents, were reduced
with GBF intake; however, the magnitude of change was not clearly reported.
Images of the colon and rectum indicated improvement in erythema, granularity, and erosion. Importantly, the study was open label with no control
group and thus could not account for the natural change in disease activity over the study duration. In addition, this study did not assess microbiota
or metabolites. Also, GBF was stated to be well tolerated, but no supporting data were presented.
In addition, Plantago ovata (psyllium) has been used in patients with UC
to identify the impact on remission maintenance.38,39 Supplementation of 20
g of P. ovata seeds a day resulted in no difference in remission maintenance
compared with mesalamine. Fecal butyrate levels increased with P. ovata intake; however, data were presented on only 7 subjects, and it was not stated
from which group these subjects originated (see Table 1).38 In addition, Fujimori and colleagues39 did not have a control group and thus any change
seen with prebiotic treatment (change in bowel function–related quality of
life) is difficult to interpret in the context of prebiotic effectiveness.
In addition to studies providing prebiotics, several investigators have
supplemented with synbiotics, a combination of prebiotics and probiotics,
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with benefit for inflammation39,40 and improvement in endoscopic score.41
These studies are not reviewed here because the probiotic component is
likely to influence gut microbiota and other measured outcomes, thus obscuring the effect of the prebiotic alone.
Limitations of current studies specifically reporting prebiotic intake in patients with IBD include inconsistency in outcomes, methods used to assess
these outcomes, and variations in disease activity. Thus far, identification of a
prebiotic that consistently addresses assumedly detrimental changes in microbiota in patients with IBD (e.g., lower F. prausnitzii) has not been done in
humans. Also, dietary intake was not assessed, thus it is not known whether
variation in diet could have affected outcomes. In addition to the lack of
available evidence, assumptions about prebiotic consumption to benefit patients with IBD are many. First, IBD risk likely originates early in life; supplementing with prebiotics may modify IBD disease activity, but it is far more
effective to create an environment amenable to ideal microbiota development early in life, whether through prebiotic supplementation or modification of other environmental stimuli. Although not emphasized earlier, CD
and UC are heterogeneous diseases; it is possible that 1 prebiotic type will
not be effective for both CD and UC. In addition to tailoring the prebiotic
to the disease type and stage, it is possible that a mixture of prebiotic fibers
will be most useful to enhance the functional capacity of a variety of bacteria that may have health benefits for patients with IBD.

Summary
Prebiotics are fermentable carbohydrates with the ability to modify gut microbiota and subsequent metabolites to improve gut health. Results from
in vitro and animal studies provide some support for the use of prebiotics
to modify a variety of factors, including intestinal-derived inflammation, a
key contributor to IBD pathogenesis. Although these studies support prebiotic use in patients with IBD, few prospective, controlled human trials exist.
In the studies that have been completed, the prebiotic used varies, making
it impossible to provide consensus on its effectiveness. In addition, limited
studies exist including functional analyses. It is important to further identify alternative prebiotics with low-bloating characteristics with minimal gas
production to provide a tolerable fiber for beneficial modulation of the microbiota, metabolite production, and inflammation reduction. In addition,
more needs to be known about mechanisms behind IBD and the specific
bacteria involved before targeted prebiotics can be effective.
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Disclosures: B.R. Hamaker is a part owner of Nutrabiotix Inc., a company that develops fibers with prebiotic capacity. Dr B.R. Hamaker’s involvement in this company has no influence on his statements regarding prebiotic effectiveness for inflammatory bowel disease.
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